Evidence map›Paper›PMID 29976137›Full record

SynthesisBMC infectious diseases2018

Medical treatment of cystic echinococcosis: systematic review and meta-analysis.

Virginia Velasco-Tirado, Montserrat Alonso-Sardón, Amparo Lopez-Bernus, Ángela Romero-Alegría, Francisco Javier Burguillo, Antonio Muro, Adela Carpio-Pérez, Juan Luis Muñoz Bellido, Javier Pardo-Lledias, Miguel Cordero and 1 more

Open access · goldAbstract readMeta-AnalysisSystematic Review
In one paragraph

Synthesis in BMC infectious diseases, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 84 papers.

0numbers the graph read from it
0cells of the map it votes in
84citing papers in PubMed
10.5field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

84 citing papers in PubMed, 169 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Archives of Razi Institute · 2025
    Review

24 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Virginia Velasco-TiradoServicio de Dermatologia, Complejo Asistencial Universitario de Salamanca (CAUSA), Universidad de Salamanca, Paseo San Vicente 58-182, 37007, Salamanca, Spain.
Montserrat Alonso-SardónCentro de Investigación de Enfermedades Tropicales de la Universidad de Salamanca (CIETUS), Universidad de Salamanca, Paseo San Vicente 58-182, 37007, Salamanca, Spain.
Amparo Lopez-BernusInstituto de investigación Biomédica de Salamanca (IBSAL), Universidad de Salamanca, Paseo San Vicente 58-182, 37007, Salamanca, Spain.
Ángela Romero-AlegríaInstituto de investigación Biomédica de Salamanca (IBSAL), Universidad de Salamanca, Paseo San Vicente 58-182, 37007, Salamanca, Spain.
Francisco Javier BurguilloDepartamento Química-Física, Facultad de Farmacia, Universidad de Salamanca, C/Donantes de Sangre s/n. Campus Unamuno, 37007, Salamanca, Spain.
Antonio MuroLaboratorio de Inmunología Parasitaria y Molecular, CIETUS, IBSAL, Facultad de Farmacia, Universidad de Salamanca, C/Donantes de Sangre s/n. Campus Unamuno, 37007, Salamanca, Spain.
Adela Carpio-PérezInstituto de investigación Biomédica de Salamanca (IBSAL), Universidad de Salamanca, Paseo San Vicente 58-182, 37007, Salamanca, Spain.
Juan Luis Muñoz BellidoInstituto de investigación Biomédica de Salamanca (IBSAL), Universidad de Salamanca, Paseo San Vicente 58-182, 37007, Salamanca, Spain.
Javier Pardo-LlediasServicio de Medicina Interna, Hospital Marqués de Valdecilla, Avenida Valdecilla 25, 39008, Santander, Cantabria, Spain. javipard2@hotmail.com.
Miguel CorderoInstituto de investigación Biomédica de Salamanca (IBSAL), Universidad de Salamanca, Paseo San Vicente 58-182, 37007, Salamanca, Spain.
Moncef Belhassen-GarcíaInstituto de investigación Biomédica de Salamanca (IBSAL), Universidad de Salamanca, Paseo San Vicente 58-182, 37007, Salamanca, Spain. mbelhassen@hotmail.com.ORCID 0000-0002-2230-1256
Universidad de Salamanca · ESMarqués de Valdecilla University Hospital · ES

Funding

Health Research Project PI16/ 01784Health Research Projects: Technological Development Project in Health DTS16/00207Proyectos Integrados IBSAL IBY15/00003
6 · The paper itself

Abstract

backgroundCystic echinococcosis (CE) is a well-known neglected parasitic disease. However, evidence supporting the four current treatment modalities is inadequate, and treatment options remain controversial. The aim of this work is to analyse the available data to answer clinical questions regarding medical treatment of CE.

methodsA thorough electronic search of the relevant literature without language restrictions was carried out using PubMed (Medline), Cochrane Central Register of Controlled Trials, BioMed, Database of Abstracts of Reviews of Effects, and Cochrane Plus databases up to February 1, 2017. All descriptive studies reporting an assessment of CE treatment and published in a peer-reviewed journal with available full-text were considered for a qualitative analysis. Randomized controlled trials were included in a quantitative meta-analysis. We used the standard methodological procedures established by the Preferred Reporting Items for Systematic Reviews and Meta-Analyses statement.

resultsWe included 33 studies related to the pharmacological treatment of CE in humans. Of these, 22 studies with levels of evidence 2 to 4 were qualitatively analysed, and 11 randomized controlled trials were quantitatively analysed by meta-analysis.

conclusionsTreatment outcomes are better when surgery or PAIR (Puncture, Aspiration, Injection of protoscolicidal agent and Reaspiration) is combined with benzimidazole drugs given pre- and/or post-operation. Albendazole chemotherapy was found to be the primary pharmacological treatment to consider in the medical management of CE. Nevertheless, combined treatment with albendazole plus praziquantel resulted in higher scolicidal and anti-cyst activity and was more likely to result in cure or improvement relative to albendazole alone.

Indexed as

AlbendazoleAnthelminticsBenzimidazolesDatabases, FactualDrug Therapy, CombinationEchinococcosisHumansNeglected DiseasesPraziquantelTreatment OutcomeAlbendazoleAnthelminticsbenzimidazoleBenzimidazolesPraziquantelAlbendazoleCystic echinococcosisEchinococcus granulosusMebendazolePraziquantel

Identifiers

PMID29976137
PMCPMC6034244
OpenAlexW2849922468

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.